Nuvectis Pharma, Inc. NVCT Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $18.58M+2.3% | $18.15M+3.4% | $17.56M+20.2% | $14.61M+4.8% | $13.94M+7.9% | ||
| $9.69M+2.8% | $9.42M+6.5% | $8.84M+5.7% | $8.36M+18.1% | $7.08M+2.2% | ||
| -$28.27M-2.5% | -$27.57M-4.4% | -$26.41M-15.0% | -$22.97M-9.3% | -$21.02M-5.9% | ||
| -$27.16M-2.7% | -$26.44M-4.2% | -$25.38M-15.0% | -$22.07M-9.5% | -$20.16M-6.1% | ||
| -$1.31+0.8% | -$1.32+3.6% | -$1.37-17.1% | -$1.17-3.5% | -$1.13-1.8% | ||
| -$1.31+0.8% | -$1.32+3.6% | -$1.37-17.1% | -$1.17-3.5% | -$1.13-1.8% | ||
| 89.3M+4.1% | 85.8M+5.8% | 81.1M+7.3% | 75.6M+6.3% | 71.2M+5.0% | ||
| 89.3M+4.1% | 85.8M+5.8% | 81.1M+7.3% | 75.6M+6.3% | 71.2M+5.0% | ||
| $1.11M-2.3% | $1.13M+9.9% | $1.03M+13.9% | $904K+5.4% | $858K+1.3% | ||
| -$28.27M-2.5% | -$27.57M-4.4% | -$26.41M-15.0% | -$22.97M-9.3% | -$21.02M-5.9% | ||
| -$28.27M-2.5% | -$27.57M-4.4% | -$26.41M-15.0% | -$22.97M-9.3% | -$21.02M-5.9% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Is Nuvectis Pharma, Inc. profitable?
- Nuvectis Pharma, Inc. is not currently profitable: it reported a net loss of $27.2M over the trailing twelve months.
- What is Nuvectis Pharma, Inc.'s earnings per share?
- Nuvectis Pharma, Inc.'s diluted EPS over the trailing twelve months is $-1.31.
- Where does Nuvectis Pharma, Inc.'s income statement data come from?
- Every line is extracted from Nuvectis Pharma, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.